Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cymabay Therapeutics (NQ: CBAY )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 32.36 (5)
Ask (Size) 32.49 (100)
Prev. Close 32.48
Today's Range N/A - N/A
52wk Range 17.47 - 32.49
Shares Outstanding 84,677,939
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 3/21
Via Investor Brand Network
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga

Performance

More News

Read More
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
From Brodsky & Smith LLC
Via GlobeNewswire
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/21
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/13
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 1/25
Via Investor Brand Network
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
From Kahn Swick & Foti, LLC
Via Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Via Benzinga
Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
6 Analysts Have This to Say About CymaBay Therapeutics
Via Benzinga
Recap: CymaBay Therapeutics Q3 Earnings
Via Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Up Triple Digits, Hits Fresh Highs
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
From Brodsky & Smith LLC
Via GlobeNewswire
Why is CymaBay (CBAY) Stock Up 25% Today?
Via InvestorPlace
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
Via Benzinga
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
Via Benzinga
Exposures Product Safety
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
Via Investor's Business Daily
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
Via Investor's Business Daily
Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.